DNLI – denali therapeutics inc. (US:NASDAQ)
Stock Stats
News
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]
Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
Form 4 Denali Therapeutics Inc. For: Nov 25 Filed by: Ho Carole
Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O.
Form 8-K Denali Therapeutics Inc. For: Nov 12
Form 4 Denali Therapeutics Inc. For: Nov 11 Filed by: Schenkein David P
Form 4 Denali Therapeutics Inc. For: Nov 07 Filed by: Schuth Alexander O.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.